Status: Recruiting
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.
Participants needed: 100
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Anders Fink-Jensen, MD, DMSciUpdated: May 14, 2026Locations: 1
Eligibility criteria
Informed oral and written consent. [+8]
Currently meeting non-cannabis/tobacco substance use disorder (ICD-10 or DSM-5). [+16]